Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab.

Brown JWL, Prados Carrasco F, Eshaghi A, Sudre CH, Button T, Pardini M, Samson RS, Ourselin S, Wheeler-Kingshott CAG, Jones JL, Coles AJ, Chard DT.

Mult Scler. 2019 Jun 6:1352458519852093. doi: 10.1177/1352458519852093. [Epub ahead of print]

PMID:
31169059
2.

Keratinocyte growth factor impairs human thymic recovery from lymphopenia.

Coles AJ, Azzopardi L, Kousin-Ezewu O, Mullay HK, Thompson SA, Jarvis L, Davies J, Howlett S, Rainbow D, Babar J, Sadler TJ, Brown JWL, Needham E, May K, Georgieva ZG, Handel AE, Maio S, Deadman M, Rota I, Holländer G, Dawson S, Jayne D, Seggewiss-Bernhardt R, Douek DC, Isaacs JD, Jones JL.

JCI Insight. 2019 May 7;5. pii: 125377. doi: 10.1172/jci.insight.125377.

3.

The immunological response to traumatic brain injury.

Needham EJ, Helmy A, Zanier ER, Jones JL, Coles AJ, Menon DK.

J Neuroimmunol. 2019 Jul 15;332:112-125. doi: 10.1016/j.jneuroim.2019.04.005. Epub 2019 Apr 11. Review.

PMID:
31005712
4.

Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.

Phelps R, Winston JA, Wynn D, Habek M, Hartung HP, Havrdová EK, Markowitz GS, Margolin DH, Rodriguez CE, Baker DP, Coles AJ.

Mult Scler. 2019 Apr 15:1352458519841829. doi: 10.1177/1352458519841829. [Epub ahead of print]

PMID:
30986126
5.

A case of anaphylaxis to alemtuzumab.

Nye CJS, Wagner A, Kousin-Ezewu O, Jones JL, Coles AJ.

J Neurol. 2019 Mar;266(3):780-781. doi: 10.1007/s00415-019-09214-2. Epub 2019 Feb 4. No abstract available.

PMID:
30715557
6.

Quantifying normal human brain metabolism using hyperpolarized [1-13C]pyruvate and magnetic resonance imaging.

Grist JT, McLean MA, Riemer F, Schulte RF, Deen SS, Zaccagna F, Woitek R, Daniels CJ, Kaggie JD, Matys T, Patterson I, Slough R, Gill AB, Chhabra A, Eichenberger R, Laurent MC, Comment A, Gillard JH, Coles AJ, Tyler DJ, Wilkinson I, Basu B, Lomas DJ, Graves MJ, Brindle KM, Gallagher FA.

Neuroimage. 2019 Apr 1;189:171-179. doi: 10.1016/j.neuroimage.2019.01.027. Epub 2019 Jan 11.

7.

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.

Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, Hartung HP, Selmaj KW, Weiner HL, Daizadeh N, Margolin DH, Chirieac MC, Compston DAS.

Mult Scler. 2018 Oct 5:1352458518796675. doi: 10.1177/1352458518796675. [Epub ahead of print]

PMID:
30289355
8.

Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation.

Khandaker GM, Oltean BP, Kaser M, Dibben CRM, Ramana R, Jadon DR, Dantzer R, Coles AJ, Lewis G, Jones PB.

BMJ Open. 2018 Sep 21;8(9):e025333. doi: 10.1136/bmjopen-2018-025333.

9.

Author response: Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Coles AJ.

Neurology. 2018 Sep 18;91(12):581-582. doi: 10.1212/WNL.0000000000006203. No abstract available.

PMID:
30224508
10.

Imaging intralesional heterogeneity of sodium concentration in multiple sclerosis: Initial evidence from 23Na-MRI.

Grist JT, Riemer F, McLean MA, Matys T, Zaccagna F, Hilborne SF, Mason JP, Patterson I, Slough R, Kaggie J, Deen SS, Graves MJ, Jones JL, Coles AJ, Gallagher FA.

J Neurol Sci. 2018 Apr 15;387:111-114. doi: 10.1016/j.jns.2018.01.027. Epub 2018 Feb 6.

11.

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL; CARE-MS II and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23.

12.

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ; CARE-MS I and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1107-1116. doi: 10.1212/WNL.0000000000004313. Epub 2017 Aug 23. Erratum in: Neurology. 2018 Apr 17;90(16):755.

13.

Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2.

Pekalski ML, García AR, Ferreira RC, Rainbow DB, Smyth DJ, Mashar M, Brady J, Savinykh N, Dopico XC, Mahmood S, Duley S, Stevens HE, Walker NM, Cutler AJ, Waldron-Lynch F, Dunger DB, Shannon-Lowe C, Coles AJ, Jones JL, Wallace C, Todd JA, Wicker LS.

JCI Insight. 2017 Aug 17;2(16). pii: 93739. doi: 10.1172/jci.insight.93739. eCollection 2017 Aug 17.

14.

Hypothyroid ataxia complicating monoclonal antibody therapy.

Badran A, Moran C, Coles AJ.

Pract Neurol. 2017 Dec;17(6):482-484. doi: 10.1136/practneurol-2017-001713. Epub 2017 Aug 4.

PMID:
28778931
15.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators.

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

16.

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.

Arnold DL, Fisher E, Brinar VV, Cohen JA, Coles AJ, Giovannoni G, Hartung HP, Havrdova E, Selmaj KW, Stojanovic M, Weiner HL, Lake SL, Margolin DH, Thomas DR, Panzara MA, Compston DA; CARE-MS I and CARE-MS II Investigators.

Neurology. 2016 Oct 4;87(14):1464-1472. Epub 2016 Sep 2.

17.

Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.

Fox EJ, Wynn D, Coles AJ, Palmer J, Margolin DH; CAMMS223 Investigators.

J Neurol Sci. 2016 Apr 15;363:188-94. doi: 10.1016/j.jns.2016.02.025. Epub 2016 Feb 12.

18.

Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series.

Azzopardi L, Cox AL, McCarthy CL, Jones JL, Coles AJ.

J Neurol. 2016 Jan;263(1):25-9.

PMID:
26477020
19.

Timing is everything in the treatment of multiple sclerosis.

McCarthy CL, Giovannoni G, Coles AJ.

BMJ Case Rep. 2015 Apr 15;2015. pii: bcr2014208960. doi: 10.1136/bcr-2014-208960.

20.

Immunotherapy for patients with acute psychosis and serum N-Methyl D-Aspartate receptor (NMDAR) antibodies: a description of a treated case series.

Zandi MS, Deakin JB, Morris K, Buckley C, Jacobson L, Scoriels L, Cox AL, Coles AJ, Jones PB, Vincent A, Lennox BR.

Schizophr Res. 2014 Dec;160(1-3):193-5. doi: 10.1016/j.schres.2014.11.001. Epub 2014 Nov 15. No abstract available.

PMID:
25468187
21.

Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes.

Zandi MS, Paterson RW, Ellul MA, Jacobson L, Al-Diwani A, Jones JL, Cox AL, Lennox B, Stamelou M, Bhatia KP, Schott JM, Coles AJ, Kullmann DM, Vincent A.

J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):708-13. doi: 10.1136/jnnp-2014-308736. Epub 2014 Sep 22.

22.

Mode of action and clinical studies with alemtuzumab.

Jones JL, Coles AJ.

Exp Neurol. 2014 Dec;262 Pt A:37-43. doi: 10.1016/j.expneurol.2014.04.018. Epub 2014 May 2. Review.

PMID:
24792641
23.

Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis.

Brown JW, Martin PJ, Thorpe JW, Michell AW, Coles AJ, Cox AL, Vincent A, Zandi MS.

J Neuroimmunol. 2014 Jun 15;271(1-2):66-8. doi: 10.1016/j.jneuroim.2014.03.012. Epub 2014 Mar 21.

PMID:
24703099
24.

Product licences for alemtuzumab and multiple sclerosis.

Coles AJ, Compston A; 70 signatories.

Lancet. 2014 Mar 8;383(9920):867-8. doi: 10.1016/S0140-6736(14)60440-2. No abstract available.

PMID:
24607095
25.

Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.

Azzopardi L, Thompson SA, Harding KE, Cossburn M, Robertson N, Compston A, Coles AJ, Jones JL.

J Neurol Neurosurg Psychiatry. 2014 Jul;85(7):795-8. doi: 10.1136/jnnp-2013-307042. Epub 2013 Dec 24.

PMID:
24368840
26.

Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation.

Jones JL, Thompson SA, Loh P, Davies JL, Tuohy OC, Curry AJ, Azzopardi L, Hill-Cawthorne G, Fahey MT, Compston A, Coles AJ.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20200-5. doi: 10.1073/pnas.1313654110. Epub 2013 Nov 26.

27.

Immune competence after alemtuzumab treatment of multiple sclerosis.

McCarthy CL, Tuohy O, Compston DA, Kumararatne DS, Coles AJ, Jones JL.

Neurology. 2013 Sep 3;81(10):872-6. doi: 10.1212/WNL.0b013e3182a35215. Epub 2013 Aug 7.

28.

First use of alemtuzumab in Balo's concentric sclerosis: a case report.

Brown JW, Coles AJ, Jones JL.

Mult Scler. 2013 Oct;19(12):1673-5. doi: 10.1177/1352458513498129. Epub 2013 Jul 25.

PMID:
23886830
29.

Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis.

Abrahamsson SV, Angelini DF, Dubinsky AN, Morel E, Oh U, Jones JL, Carassiti D, Reynolds R, Salvetti M, Calabresi PA, Coles AJ, Battistini L, Martin R, Burt RK, Muraro PA.

Brain. 2013 Sep;136(Pt 9):2888-903. doi: 10.1093/brain/awt182. Epub 2013 Jul 17.

30.

Alemtuzumab treatment of multiple sclerosis.

Coles AJ.

Semin Neurol. 2013 Feb;33(1):66-73. doi: 10.1055/s-0033-1343797. Epub 2013 May 25. Review.

PMID:
23709214
31.

Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.

Brown JW, Coles AJ.

Drug Des Devel Ther. 2013;7:131-8. doi: 10.2147/DDDT.S32687. Epub 2013 Mar 6. Review.

32.

Alemtuzumab therapy for multiple sclerosis.

Coles AJ.

Neurotherapeutics. 2013 Jan;10(1):29-33. doi: 10.1007/s13311-012-0159-0. Review.

33.

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators.

Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1.

PMID:
23122652
34.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
35.

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.

Neurology. 2012 Apr 3;78(14):1069-78. doi: 10.1212/WNL.0b013e31824e8ee7. Epub 2012 Mar 21.

PMID:
22442431
36.

Antibody-mediated encephalitis: a treatable cause of schizophrenia.

Lennox BR, Coles AJ, Vincent A.

Br J Psychiatry. 2012 Feb;200(2):92-4. doi: 10.1192/bjp.bp.111.095042.

PMID:
22297586
37.

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.

Hill-Cawthorne GA, Button T, Tuohy O, Jones JL, May K, Somerfield J, Green A, Giovannoni G, Compston DA, Fahey MT, Coles AJ.

J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):298-304. doi: 10.1136/jnnp-2011-300826. Epub 2011 Nov 5.

PMID:
22056965
38.

A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.

Cuker A, Coles AJ, Sullivan H, Fox E, Goldberg M, Oyuela P, Purvis A, Beardsley DS, Margolin DH.

Blood. 2011 Dec 8;118(24):6299-305. doi: 10.1182/blood-2011-08-371138. Epub 2011 Sep 29.

39.

'Radiologically compatible CLIPPERS' may conceal a number of pathologies.

Jones JL, Dean AF, Antoun N, Scoffings DJ, Burnet NG, Coles AJ.

Brain. 2011 Aug;134(Pt 8):e187. doi: 10.1093/brain/awr134. Epub 2011 Jun 7. No abstract available.

PMID:
21653537
40.

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.

Lancet Neurol. 2011 Apr;10(4):338-48. doi: 10.1016/S1474-4422(11)70020-5.

PMID:
21397567
41.

Disease-relevant autoantibodies in first episode schizophrenia.

Zandi MS, Irani SR, Lang B, Waters P, Jones PB, McKenna P, Coles AJ, Vincent A, Lennox BR.

J Neurol. 2011 Apr;258(4):686-8. doi: 10.1007/s00415-010-5788-9. Epub 2010 Oct 26. No abstract available.

42.

Human fetal neural precursor cells can up-regulate MHC class I and class II expression and elicit CD4 and CD8 T cell proliferation.

Laguna Goya R, Busch R, Mathur R, Coles AJ, Barker RA.

Neurobiol Dis. 2011 Feb;41(2):407-14. doi: 10.1016/j.nbd.2010.10.008. Epub 2010 Oct 16.

PMID:
20955796
43.

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, Webber DJ, Compston DA, Coles AJ.

Brain. 2010 Aug;133(Pt 8):2232-47. doi: 10.1093/brain/awq176. Epub 2010 Jul 21.

PMID:
20659956
44.

New treatment strategies in multiple sclerosis.

Jones JL, Coles AJ.

Exp Neurol. 2010 Sep;225(1):34-9. doi: 10.1016/j.expneurol.2010.06.003. Epub 2010 Jun 12. Review.

PMID:
20547155
45.

A novel strategy to reduce the immunogenicity of biological therapies.

Somerfield J, Hill-Cawthorne GA, Lin A, Zandi MS, McCarthy C, Jones JL, Willcox M, Shaw D, Thompson SA, Compston AS, Hale G, Waldmann H, Coles AJ.

J Immunol. 2010 Jul 1;185(1):763-8. doi: 10.4049/jimmunol.1000422. Epub 2010 Jun 2.

46.

Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy.

Marsh EA, Hirst CL, Llewelyn JG, Cossburn MD, Reilly MM, Krishnan A, Doran M, Ryan AM, Coles AJ, Jones JL, Robertson NP.

J Neurol. 2010 Jun;257(6):913-9. doi: 10.1007/s00415-009-5437-3. Epub 2010 Jan 6.

PMID:
20049473
47.

Spotlight on alemtuzumab.

Jones JL, Coles AJ.

Int MS J. 2009 Sep;16(3):77-81. Review.

PMID:
19878629
48.

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

Thompson SA, Jones JL, Cox AL, Compston DA, Coles AJ.

J Clin Immunol. 2010 Jan;30(1):99-105. doi: 10.1007/s10875-009-9327-3. Epub 2009 Sep 10.

PMID:
19763798
49.

Monoclonal antibodies in multiple sclerosis treatment: current and future steps.

Helliwell CL, Coles AJ.

Ther Adv Neurol Disord. 2009 Jul;2(4):195-203. doi: 10.1177/1756285609337827. No abstract available.

50.

IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).

Jones JL, Phuah CL, Cox AL, Thompson SA, Ban M, Shawcross J, Walton A, Sawcer SJ, Compston A, Coles AJ.

J Clin Invest. 2009 Jul;119(7):2052-61. doi: 10.1172/JCI37878. Epub 2009 Jun 22.

Supplemental Content

Loading ...
Support Center